We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Cancer scientists overestimate the extent to which high-profile preclinical studies can be successfully replicated, new research from McGill University suggests.
The positive outcome from the clinical phase IIa CHIC study and the preclinical studies have now convinced NeuroVive to proceed into the next stage of clinical development.